



Abstract Submission Guidelines
11th Annual International Coronary Congress

SUBMISSION DEADLINE: Monday, June 9th, 2025
23:59 Eastern Time (New York)

Abstract and Cases deemed appropriate for presentation before the International Coronary Congress (ICC) will have the following characteristics:

- Original, new and significant scientific work.
- Major updates and/or significant follow-up on established procedures and/or research.
- Additional definition of previous studies that modify in a major way an understanding of techniques or technologies.
- The submitted Abstract should not be similar to work submitted to, or under consideration by, other organizations and/or journals.

ABSTRACT PREPARATION AND SUBMISSION INSTRUCTIONS

- Abstracts must be submitted electronically. The deadline is **Monday, June 9th, 2025 at 11:59 PM, Eastern Time** (New York).
- Total abstract word limit is 350. There is a minimum word count of 50 words.
- There are two presentation formats: Oral Presentation and e-Poster Presentation. When submitting an abstract, one of the following options must be selected:
 - Oral Presentation
 - Oral or e-Poster Presentation
 - e-Poster Presentation Only

Please note the final presentation format will be determined by the ISCAS Program Committee.

ABSTRACT FORMAT

All abstracts must be structured using the following section headings:

Objective: A brief statement of the purpose of the study and the current state of research in the field.

Methods: The methods of study or experimental approach should be clearly, but briefly, defined

Results: A summary of the results of the study, including sufficient details to support those conclusions. These may be presented in a brief table.

Conclusions: A statement concerning the significance of the work and its possible implications for clinical practice and for future research.

ABSTRACT FORMAT (CONTINUED)

- Type the abstract in English within the box provided. The abstract title must be in title case, flush with the left margin of the box. Use upper and lower case letters as appropriate for abbreviations in the title.
- Up to one (1) table, image or figure may be used within your abstract.
- **No reference should be made in the abstract to the names or institutions of the authors.**
- Accepted abstracts will appear in the program and online as submitted. Please double check your work to ensure it is complete.

ABSTRACT SUBMISSION CATEGORIES

To facilitate the review and selection process, abstracts should be submitted in one of the listed categories. There are no quotas or caps on any of the categories; all complete submissions will be reviewed.

- CABG in Women
- Off-pump CABG
- Best Practices in Cardiopulmonary Bypass and Cardioplegia
- Minimally Invasive + Robotic CABG (MIDCAB/MICS/LAST) + Hybrid CABG
- Conduit Configuration, Harvesting Techniques and Alternative Conduits
- Novel Techniques and Technologies in CABG
- ERAS after CABG/CABG Pathways
- Outcomes in CABG
- Atrial Fibrillation Management in CABG
- Heart Failure and CABG
- Coronary Imaging Angiography, CT FFR, MRI, Nuclear Stress
- Relative Efficacy of CABG and PCI
- Management of Ischemic Mitral Regurgitation during CABG
- Challenging CABG Cases
- Infection Prevention and Treatment
- Management of CAD
- Quality Control in CABG
- Prevention and Treatment of Surgical Site Infection in CABG
- Coronary Misc.

DISCLOSURE REQUIREMENTS

One of the founding principles of the ICC is the acknowledgement of interaction between industry and surgeons to facilitate rapid development of technology and techniques to treat heart valve disease. In that endeavor, a surgeon may become financially involved with the company that translates his or her idea into reality. The ICC does not object to that relationship, but requires that all those submitting abstracts and presenting papers disclose financial or consulting relationships with companies that may be involved with production or marketing of technology being discussed.

The need for disclosure extends to unrestricted laboratory grants. In addition, any off-label use of an FDA-approved product, or any use of a non-FDA approved device must be disclosed. **When you complete your abstract submission, you will be required to complete disclosure information for ALL authors.**

- Disclose any relevant financial relationships for any and all authors listed in the title string. Specific definitions are included in the online submission process.
- Be prepared to speak with the Program Committee Chair to resolve any disclosed conflicts.
- In the event your work is selected for presentation, list all disclosed conflicts on a slide placed at the beginning of your presentation.

In order to comply with the ACCME Updated Standards for Commercial Support, Cine-Med as the accredited CME provider of this activity, has implemented a disclosure process to ensure that anyone who is in a position to control the content of the educational activity has disclosed to us all relevant financial relationships with any commercial interest as it pertains to the content of the presentation. The goal of this process is not to exclude people who have conflicts, but to manage these conflicts while benefiting from your expertise.

Should it be determined that a conflict of interest exists as a result of a financial relationship you may have, you will be contacted and methods to resolve the conflict will be discussed with you. **In addition, all affirmative disclosures must be revealed by a slide at the beginning of the presentation and must be acknowledged from the podium. Failure or refusal to disclose or the inability to resolve the identified conflict may result in the withdrawal of the invitation to participate.**

If you have difficulty uploading files or navigating the abstract submission site, please contact technical assistance:

support@abstractsonline.com or 1-217-398-1792

If you have questions regarding submission policies, presentation formats and author requirements please contact the ICC meetings department:

meetings@internationalcoronarycongress.com or 1-978-927-8330